TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma

Journal of the National Cancer Institute

Volumn 106, Issue 9, 2014, Pages

  Griewank, Klaus G ^a   Murali, Rajmohan ^b   Puig Butille, Joan Anton ^c   Schilling, Bastian ^a   Livingstone, Elisabeth ^a   Potrony, Miriam ^c   Carrera, Cristina ^c,d   Schimming, Tobias ^a   Möller, Inga ^a   Schwamborn, Marion ^a   Sucker, Antje ^a   Hillen, Uwe ^a   Badenas, Celia ^c,e   Malvehy, Josep ^c,d   Zimmer, Lisa ^a   Scherag, André ^f   Puig, Susana ^c,d   Schadendorf, Dirk ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME; COHORT ANALYSIS; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; DNA ISOLATION; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; ONCOGENE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; THICKNESS; CANCER OF UNKNOWN PRIMARY SITE; GENETICS; KAPLAN MEIER METHOD; MELANOMA; METASTASIS; MORTALITY; MUCOSA; MUTATION; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RADIATION EXPOSURE; RISK; SKIN TUMOR; ULTRAVIOLET RADIATION;

HUMANS; KAPLAN-MEIER ESTIMATE; MELANOMA; MUCOUS MEMBRANE; MUTATION; NEOPLASMS, UNKNOWN PRIMARY; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; SKIN NEOPLASMS; TELOMERASE; ULTRAVIOLET RAYS;

EID: 84929465598     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju246     Document Type: Article

References (32)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
2. Albino AP, Le Strange R, Oliff AI, et al. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature. 1984;308(5954):69-72.
3. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-4346.
4. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147.
5. Guldberg P, Thor Straten P, Birck A, et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997;57(17):3660-3663.
6. Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44(9):1006-1014.
7. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012;150(2):251-63.
8. Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011;43(5):442-446.
9. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957-959.
10. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959-961.
11. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021-6026.
12. Griewank KG, Murali R, Schilling B, et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer. 2013;109(2):497-501.
13. Landa I, Ganly I, Chan TA, et al. Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease. J Clin Endocrinol Metab. 2013;98(9):E1562-E1566.
14. Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.
15. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
16. Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004;3(1):6.
17. Griewank K, Westekemper H, Murali R, et al. Conjunctival Melanomas harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. Clin Cancer Res. 2013;19 (12) 3143-3152.
18. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191-2199.
19. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463(7278):191-196.
20. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991;88(22):10124-10128.
21. Griewank K, Schilling B, Murali R, et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol. 2014;27(4):502-508.
22. Griewank KG, Murali R, Schilling B, et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One. 2013;8(11):e80354.
23. Scott GA, Laughlin TS, Rothberg PG. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol. 2014;27(4):516-523
24. Puig-Butille JA, Badenas C, Ogbah Z, et al. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma. Exp Dermatol. 2013;22(2):148-150.
25. Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 2000;60(7):1968-1973.
26. Diaz A, Puig-Butille JA, Valera A, et al. TERT and AURKA Gene Copy Number Gains Enhance the Detection of Acral Lentiginous Melanomas by Fluorescence in Situ Hybridization. J Mol Diagn. 2013;16(2):198-206.
27. Mann GJ, Pupo GM, Campain AE, et al. BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. J Invest Dermatol. 2012;133(2):509-517.
28. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014-4023.
29. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-1246.
30. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett. 2005;579(4):859-862.
31. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell. 2013;152(3):390-393.
32. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.